Interstitial lung disease points to consider for clinical trials in systemic sclerosis

Dinesh Khanna; James Seibold; Jonathan Goldin; Donald P Tashkin; Daniel E Furst; Athol Wells

doi:10.1093/rheumatology/kex203

Interstitial lung disease points to consider for clinical trials in systemic sclerosis

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v27-v32. doi: 10.1093/rheumatology/kex203.

Authors

Dinesh Khanna¹, James Seibold², Jonathan Goldin³, Donald P Tashkin⁴, Daniel E Furst⁵, Athol Wells⁶

Affiliations

¹ Department of Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI.
² Scleroderma Consultants LLC, Litchfield, CT.
³ Department of Radiological Science.
⁴ Department of Medicine-Pulmonology.
⁵ Department of Rheumatology, David Geffen School of Medicine, Los Angeles, CA, USA.
⁶ Department of Medicine, Royal Brompton Hospital, Faculty of Medicine, London, UK.

Abstract

Interstitial lung disease causes major morbidity and mortality in patients with systemic sclerosis (SSc-ILD). Large randomized clinical trials in SSc-ILD have provided important information regarding the feasibility, reliability and validity of outcome measures. Forced vital capacity percentage predicted should be considered as a primary outcome measure, with inclusion of appropriate radiological and patient-reported measures. We provide practical recommendations for trial design in SSc-ILD.

Keywords: interstitial lung disease clinical trials; lung disease; scleroderma.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Clinical Trials as Topic / methods*
Disease Management*
Global Health
Humans
Lung Diseases, Interstitial* / diagnosis
Lung Diseases, Interstitial* / etiology
Lung Diseases, Interstitial* / therapy
Scleroderma, Systemic / complications*
Scleroderma, Systemic / mortality
Survival Rate